Daiichi Sankyo Drug Pipeline

Daiichi Sankyo maintains a substantial clinical portfolio, with 49 active trials out of 203 registered since 2008. Clinical activity spans nine therapeutic areas, though with a pronounced concentration in oncology, which accounts for 64 active trials, or 131% of active programs when considering multi-indication trials. Within oncology, the pipeline is focused on solid tumors, particularly advanced solid tumors, with 14 active trials including two in Phase 3. Non-small cell lung cancer (NSCLC) also represents a significant area of activity, with 12 active trials and five in Phase 3. Breast cancer is another key indication within the oncology portfolio, with seven active trials, four of which are in Phase 3. Lung cancer (general) and prostate cancer have three active trials each. Outside of oncology, the portfolio includes one active trial in metabolic disorders. The weighting toward Phase 3 trials in key oncology indications suggests a focus on near-term clinical catalysts.